Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus MD 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 370 IN PLASTIC CONTAINER versus MD 76.
IOPAMIDOL-370 IN PLASTIC CONTAINER vs MD-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, low-osmolality radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing the contrast of vascular structures and tissues during imaging. It does not have a specific molecular target but relies on its iodine content for radiopacity.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Intravenous: 0.5-2 mL/kg (185-740 mg iodine/kg) as a single dose; repeated doses may be administered up to a total of 5 mL/kg (1850 mg iodine/kg) within a 24-hour period.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
None Documented
None Documented
Terminal half-life 1.5–2 hours in normal renal function; prolonged to 4–12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Renal: >90% unchanged by glomerular filtration within 24–48 hours; biliary/fecal: <2%.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent